ARMP Stock Analysis: Buy, Sell, or Hold?
ARMP - Armata Pharmaceuticals, Inc. Common Stock
$7.01
0.14 (2.04%)
▲
5d:
+1.45%
30d:
-14.82%
90d:
-13.35%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ARMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARMP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ARMP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ARMP is currently trading at $7.01, which is considered oversold relative to its 30-day fair value range of $7.18 to $8.13.
Technical Outlook: Technically, ARMP is showing sideways momentum. Immediate support is located at $6.37, while resistance sits at $8.04.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (81th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $17.50 (+149.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARMP is showing sideways momentum. Immediate support is located at $6.37, while resistance sits at $8.04.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Implied Volatility is high (81th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $17.50 (+149.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.18 -
$8.13
Company Quality Score
48/100
(HOLD)
Options IV Signal
81th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 81th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 149.6% below Wall St target ($17.50)
Trading Range Analysis
30-Day Trading Range
$7.18 -
$8.13
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.09
(29.8%)
Support & Resistance Levels
Support Level
$6.37
Resistance Level
$8.05
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.23
Wall Street Target
$17.50
(+149.6%)
Revenue Growth (YoY)
60.7%
Share & Embed Analysis
Last updated: June 24, 2026 2:31 AM ET
Data refreshes hourly during market hours. Next update: 3:31 AM
Data refreshes hourly during market hours. Next update: 3:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARMP showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
